Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press14610.17650/1726-9776-2013-9-4-47-51PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫLOW-DOSE RATE BRACHYTHERAPY FOR PROSTATE CANCER: DIFFERENT INDICATIONS – DIFFERENT RESULTSНИЗКОДОЗНАЯ БРАХИТЕРАПИЯ ПРИ РАКЕ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ: РАЗЛИЧНЫЕ ПОКАЗАНИЯ – РАЗЛИЧНЫЕ РЕЗУЛЬТАТЫBiryukovV. A.БирюковВ. А.
Russian Federation
vitbirukov@mail.ruMedical Radiology Research Center, Ministry of Health of the Russian Federation, ObninskФГБУ МРНЦ МЗ РФ, Обнинск301220139447512907201429072014https://oncourology.abvpress.ru/oncur/article/view/146

In Russia, there is presently a growing interest in low-dose intratissue radiotherapy (brachytherapy) for locally advanced prostate cancer (PC). Since its inception, current brachytherapy has undergone a number of significant changes in terms of improved visualization and better treatment planning and monitoring, which is sure to have affected the higher quality of their performance and better long-term results. The main purpose of the given paper is to generalize the data of foreign investigators who have the greatest experience with brachytherapy for its further use in the treatment of patients with locally advanced PC under the conditions of Russian clinics.

В настоящее время в России возрастает интерес к проведению низкодозной внутритканевой лучевой терапии (брахитерапии) при локализованном раке предстательной железы (РПЖ). Современная брахитерапия с момента своего внедрения претерпела ряд значимых изменений в плане улучшения визуализации, планирования и контроля проводимого лечения, что, несомненно, отразилось на повышении качества ее выполнения и улучшении отдаленных результатов. Основной целью представленной работы является обобщение данных зарубежных исследователей, имеющих наибольший опыт в области брахитерапии для дальнейшего применения в лечении пациентов с локализованным РПЖ в условиях отечественных клиник.

prostate cancerlow-dose intratissue radiotherapybrachytherapyindications for brachytherapylong-term resultsрак предстательной железынизкодозная внутритканевая лучевая терапиябрахитерапияпоказания к брахитерапииотдаленные результаты1. Holm H. H., Juul N., Pedersen J. F. et al. Transperineal 125 iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983;130 (2):283–6.Holm H. H., Juul N., Pedersen J. F. et al. Transperineal 125 iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983;130 (2):283–6.2. http://www.roszdravnadzor.ru/ais/register/3180http://www.roszdravnadzor.ru/ais/register/31803. Guidelines on prostate cancer. European Association of Urology Web site. http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20II. pdfGuidelines on prostate cancer. European Association of Urology Web site. http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20II. pdf4. Davis B. J. Horwitz E. M., Lee W. R. et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound – guided permanent brachytherapy. Brachytherapy 2012;11:6–19.Davis B. J. Horwitz E. M., Lee W. R. et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound – guided permanent brachytherapy. Brachytherapy 2012;11:6–19.5. Merrick G., Butler W., Lief J., Dorsey A. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;47:121–128.Merrick G., Butler W., Lief J., Dorsey A. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;47:121–128.6. Wallner K., Lee H., Wasserman S., Dattoli M. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997;37(3):565–9.Wallner K., Lee H., Wasserman S., Dattoli M. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997;37(3):565–9.7. Hughes S., Wallner K., Merrick G., Miller S. еt al. Preexisting histologic evidence of prostatitis is unrelated to postimplant urinary morbidity. Int J Cancer 2001;96 Suppl:79–82.Hughes S., Wallner K., Merrick G., Miller S. еt al. Preexisting histologic evidence of prostatitis is unrelated to postimplant urinary morbidity. Int J Cancer 2001;96 Suppl:79–82.8. Grann A., Wallner K. Prostate brachytherapy in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys 1998;40 (1):135–8.Grann A., Wallner K. Prostate brachytherapy in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys 1998;40 (1):135–8.9. Merrick G. S., Butler W. M., Wallner K. E. et al. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 2004; 64 (4):754–9.Merrick G. S., Butler W. M., Wallner K. E. et al. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 2004; 64 (4):754–9.10. Cheung A. K., Chen M. H., Moran B. J. et al. The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statement. Brachytherapy 2010; 9:145–50.Cheung A. K., Chen M. H., Moran B. J. et al. The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statement. Brachytherapy 2010; 9:145–50.11. Blasko J. C., Grimm P. D., Sylvester J. E. et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46 (4):839–50.Blasko J. C., Grimm P. D., Sylvester J. E. et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46 (4):839–50.12. Zelefsky M. J., Hollister T., Raben A. et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000;47 (5):1261–6.Zelefsky M. J., Hollister T., Raben A. et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000;47 (5):1261–6.13. Grimm P. D., Blasko J. C., Sylvester J. E. et al. 10‑year biochemical (prostate-specific antigen) control of prostate cancer with (125) I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51(1):31–40.Grimm P. D., Blasko J. C., Sylvester J. E. et al. 10‑year biochemical (prostate-specific antigen) control of prostate cancer with (125) I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51(1):31–40.14. Stone N. N., Stock R. G., Unger P. Intermediate term biochemical-free progression and local control following 125 iodine brachytherapy for prostate cancer. J Urol 2005;173(3):803–7.Stone N. N., Stock R. G., Unger P. Intermediate term biochemical-free progression and local control following 125 iodine brachytherapy for prostate cancer. J Urol 2005;173(3):803–7.15. Potters L., Morgenstern C., Calugaru E. et al. 12‑year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005;173 (5):1562–6.Potters L., Morgenstern C., Calugaru E. et al. 12‑year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005;173 (5):1562–6.16. Stone N. N., Stone M. M., Rosenstein B. S. et al. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostatebrachytherapy. J Urol 2011;185 (2):495–500.Stone N. N., Stone M. M., Rosenstein B. S. et al. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostatebrachytherapy. J Urol 2011;185 (2):495–500.17. Vargas C., Swartz D., Vashi A. et al. Longterm outcomes and prognostic factors in patients treated with intraoperatively planned prostate brachytherapy. Brachytherapy 2013;12:120–125.Vargas C., Swartz D., Vashi A. et al. Longterm outcomes and prognostic factors in patients treated with intraoperatively planned prostate brachytherapy. Brachytherapy 2013;12:120–125.18. Blasko J. C., Grimm P. D., Sylsvester J. E., Cavanagh W. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000;57 (3):273–8.Blasko J. C., Grimm P. D., Sylsvester J. E., Cavanagh W. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000;57 (3):273–8.19. Grimm P. D., Blasko J. C., Sylvester J. E. et al. 10‑year biochemical (prostate-specific antigen) control of prostate cancer with (125) I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51 (1):31–40.Grimm P. D., Blasko J. C., Sylvester J. E. et al. 10‑year biochemical (prostate-specific antigen) control of prostate cancer with (125) I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51 (1):31–40.20. Battermann J. J., Boon T. A., Moerland M. A. Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiother Oncol 2004;71 (1):23–8.Battermann J. J., Boon T. A., Moerland M. A. Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiother Oncol 2004;71 (1):23–8.21. Zelefsky M. J., Kuban D. A., Levy L. B. et al. Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007;67:327–33.Zelefsky M. J., Kuban D. A., Levy L. B. et al. Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007;67:327–33.22. Frank S. J., Arterbery V. E., Hsu I. C. et al. American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer. Brachytherapy 2011;10:357–62.Frank S. J., Arterbery V. E., Hsu I. C. et al. American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer. Brachytherapy 2011;10:357–62.23. Dattoli M., Wallner K., Blasko J. Prostate Brachytherapy Made Complicated. Smart Medicine Press, Seattle, Wash, USA, 2nd edition, 2001.Dattoli M., Wallner K., Blasko J. Prostate Brachytherapy Made Complicated. Smart Medicine Press, Seattle, Wash, USA, 2nd edition, 2001.24. Sohayda C., Kupelian P. A., Levin H. S. et al. Extent of extra-capsular extension in localized prostate cancer. Urology 2000;55 (3):382–6.Sohayda C., Kupelian P. A., Levin H. S. et al. Extent of extra-capsular extension in localized prostate cancer. Urology 2000;55 (3):382–6.25. Teh B. S., Bastasch M. D., Mai W. Y. et al. Predictors of extracapsular extension and its radial distance in prostate cancer: implications for prostate IMRT, brachytherapy, and surgery. Cancer J 2003;9(6):454–60.Teh B. S., Bastasch M. D., Mai W. Y. et al. Predictors of extracapsular extension and its radial distance in prostate cancer: implications for prostate IMRT, brachytherapy, and surgery. Cancer J 2003;9(6):454–60.26. Merrick G. S., Butler W. M., Wallner K. E. et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005;61 (1):32–43.Merrick G. S., Butler W. M., Wallner K. E. et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005;61 (1):32–43.27. Critz F. A., Levinson K. 10‑year diseasefree survival rates after simultaneousirradiation for prostate cancer with a focus on calculation methodology. J Urology 2004;172 (6, part 1): 2232–8.Critz F. A., Levinson K. 10‑year diseasefree survival rates after simultaneousirradiation for prostate cancer with a focus on calculation methodology. J Urology 2004;172 (6, part 1): 2232–8.28. Dattoli M., Wallner K., True L. et al. Longterm outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with brachytherapy and supplemental external beam radiotherapy. J Oncol 2010;2010: article ID 471375.Dattoli M., Wallner K., True L. et al. Longterm outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with brachytherapy and supplemental external beam radiotherapy. J Oncol 2010;2010: article ID 471375.29. Stock R. G., Cesaretti J. A., Stone N. N. Comparisons of PSA failure definitions following trimodality therapy for intermediate to high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2007;69 (3):344–5.Stock R. G., Cesaretti J. A., Stone N. N. Comparisons of PSA failure definitions following trimodality therapy for intermediate to high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2007;69 (3):344–5.30. Lee L. N., Stock R. G., Stone N. N. Role of hormonal therapy in the management of intermediate to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002;52(2):444–52.Lee L. N., Stock R. G., Stone N. N. Role of hormonal therapy in the management of intermediate to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002;52(2):444–52.31. Merrick G. S. The role of hormonal therapy in prostate brachytherapy. Counterpoint. Brachytherapy 2003; 2 (1):2–4.Merrick G. S. The role of hormonal therapy in prostate brachytherapy. Counterpoint. Brachytherapy 2003; 2 (1):2–4.32. Zilli T., Boudreau C., Filion E. J. et al. Combined intensity-modulated radiation therapy vs. three-dimensional highly conformal radiotherapy after 125I prostate permanent seed brachytherapy: A comparative treatment planning study. Brachytherapy 2011;10: 416–20.Zilli T., Boudreau C., Filion E. J. et al. Combined intensity-modulated radiation therapy vs. three-dimensional highly conformal radiotherapy after 125I prostate permanent seed brachytherapy: A comparative treatment planning study. Brachytherapy 2011;10: 416–20.33. Fang L. C., Merrick G. S., Butler W. M. et al. High-risk prostate cancer with Gleason score 8–10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011;81 (4):992–6.Fang L. C., Merrick G. S., Butler W. M. et al. High-risk prostate cancer with Gleason score 8–10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011;81 (4):992–6.34. Bittner N., Merrick G. S., Butler W. M. et al. Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy. Brachytherapy 2012;11 (4):250–5.Bittner N., Merrick G. S., Butler W. M. et al. Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy. Brachytherapy 2012;11 (4):250–5.35. Carpenter T. J., Forsythe K., Kao J. et al. Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy. Brachytherapy 2011;10:261–8.Carpenter T. J., Forsythe K., Kao J. et al. Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy. Brachytherapy 2011;10:261–8.